Noah Goodman - 02 Mar 2026 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role: Chief Business Officer
Signature: /s/ Bruce Jacobs, as Attorney-in-Fact
Issuer symbol: KYMR
Transactions as of: 02 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 04 Mar 2026, 18:00:08 UTC
Previous filing: 09 Apr 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Goodman Noah	Chief Business Officer	500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN	/s/ Bruce Jacobs, as Attorney-in-Fact	04 Mar 2026	0002060075

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KYMR	Common Stock	Award		+9,225	+18%	$0.000000^*	59,306	02 Mar 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KYMR	Stock Option (Right to Buy)	Award		+18,450		$0.000000^*	18,450	02 Mar 2026	Common Stock	18,450	$90.10	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.
F2	The shares underlying this stock option shall vest in fourty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.